Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients With Recurrent Ovarian Cancer

NCT04742075 is registered in ClinicalTrials.gov with Nordic Society of Gynaecological Oncology - Clinical Trials Unit as lead sponsor.

NCT NCT04742075
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04742075 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients With Recurrent Ovarian Cancer
Lead sponsor
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 15, 2021
Completion date
December 31, 2030
Enrollment
188 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer